Serimmune, Merck reach drug discovery milestone

By The Science Advisory Board staff writers

April 3, 2020 -- Serimmune has used its immune mapping technology on clinical and preclinical samples provided by Merck.

The collaboration included Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to help identify antigens that stimulate immunity. The goal is to develop and commercialize promising agents.

Serimmune can receive payments related to research, development, and regulatory milestones as well as tiered royalty payments on sales arising from products that result from the partnership, the company noted.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.